臨床薬理
特集/臨床試験とバイオマーカー
1.動脈硬化性疾患のバイオマーカー
植田 真一郎
著者情報
ジャーナル フリー

41 巻 (2010) 3 号 p. 90-94

詳細
PDFをダウンロード (233K) 発行機関連絡先
抄録

The principal aim of the intervention against established cardiovascular risk factors including hypertension, dyslipidemia and diabetes is the prevention of atherosclerotic cardiovascular event. Indeed there is no doubt that reduction of blood pressure, for example, is associated with better outcome. However, achieved of blood pressure does not necessarily reflect regression of atherosclerosis. Blood pressure as well as other risk factors, therefore, may not be suitable for the assessment of progression of atherosclerosis particularly at the early stage. Although the criteria of surrogacy is not easily satisfied, surrogate markers that integrate risk factors and more directly reflect development of atherosclerosis are warranted in clinical practice for individual patient as well as in early phase clinical trial of anti-atherosclerotic therapy.

著者関連情報
© 2010 日本臨床薬理学会
前の記事 次の記事

閲覧履歴
feedback
Top